Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments.

Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes ...

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...

The recent achievement of durable engraftment of adoptively transferred T cells endowed with a CAR and costimulatory molecule provides an extraordinary opportunity to implement novel immunotherapies ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...